Marek Słomczyński
Research Subjects
Marek Słomczyński has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Paweł Burchardt
Klinika Intensywnej Terapii Kardiologicznej, Uniwersytet Medyczny im. K. Marcinkowskiego, Poznań
3 shared publications - Dominika Kasprzak
Department of Cardiology, J. Strus Hospital, Poznan, Poland
2 shared publications - Jan Budzianowski
Department of Interventional Cardiology and Cardiac Surgery, University of Zielona Gora, Collegium Medicum, Zielona Gora, Poland
2 shared publications - Janusz Rzeźniczak
Department of Cardiology, J. Strus Hospital, 61-285 Poznań, Poland
2 shared publications - Dariusz Hiczkiewicz
Department of Interventional Cardiology and Cardiac Surgery, University of Zielona Gora, Collegium Medicum, Zielona Gora, Poland, Poland
1 shared publication - Dariusz Hiczkiewicz
Department of Interventional Cardiology and Cardiac Surgery, Collegium Medicum, University of Zielona Góra, 65-046 Zielona Góra, Poland
1 shared publication
Latest Publications
- Open Access
- 29 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (11) , 1705
Evaluation of Clinical and Genetic Determinants of Rivaroxaban Pharmacokinetics and Coagulation Parameters in Patients with Cardiovascular Diseases: An Exploratory Observational Study
Purpose: Interindividual variability in rivaroxaban exposure remains incompletely understood and may contribute to differences in treatment outcomes. This study aimed to investigate associations between polymorphisms in CYP3A4 (rs2242480), CYP2J2 (rs890293), and ABCB1 (rs1045642, rs2032582) genes, clinical factors and rivaroxaban pharmacokinetics. Methods: The study included 66 patients receiving 20 mg of rivaroxaban once daily. Rivaroxaban concentrations in plasma and dried blood spots were determined using a validated UPLC-MS/MS method. Genotyping was performed using PCR-RFLP. Associations between pharmacokinetic parameters, genetic variants and anthropometric characteristics, concomitant medications, comorbidities, and coagulation parameters were assessed using appropriate statistical analyses. Results: Carriers of the ABCB1 rs2032582 G allele exhibited lower rivaroxaban exposure, as reflected by reduced AUC0–12h values compared with non-carriers (1817.43 ± 703.70 vs. 2442.96 ± 691.13 ng·h/mL, nominal p = 0.0369). Concomitant use of eplerenone was associated with increased rivaroxaban exposure. Body mass composition and impaired renal function were associated with rivaroxaban concentrations. In addition, associations between CYP3A4 rs2242480 genotype and several body size descriptors, including body weight or lean body mass, and selected coagulation parameters were observed in exploratory analyses. However, most nominal associations did not remain statistically significant after correction for multiple comparisons. After Benjamini–Hochberg correction, only impaired renal function, drug interactions and biological sex remained statistically significant factors, impacting rivaroxaban’s pharmacokinetics and anticoagulant parameters. Conclusions: Several genetic and clinical factors showed nominal association with rivaroxaban pharmacokinetics and coagulation parameters in this study. These findings should be interpreted as exploratory given the limited sample size and the number of statistical comparisons. Further studies in larger cohorts are needed to clarify the clinical relevance of genetic and clinical determinants of rivaroxaban exposure.
- 29 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (11) , 1705
Open AccessEvaluation of Clinical and Genetic Determinants of Rivaroxaban Pharmacokinetics and Coagulation Parameters in Patients with Cardiovascular Diseases: An Exploratory Observational Study
Purpose: Interindividual variability in rivaroxaban exposure remains incompletely understood and may contribute to differences in treatment outcomes. This study aimed to investigate associations between polymorphisms in CYP3A4 (rs2242480), CYP2J2 (rs890293), and ABCB1 (rs1045642, rs2032582) genes, clinical factors and rivaroxaban pharmacokinetics. Methods: The study included 66 patients receiving 20 mg of rivaroxaban once daily. Rivaroxaban concentrations in plasma and dried blood spots were determined using a validated UPLC-MS/MS method. Genotyping was performed using PCR-RFLP. Associations between pharmacokinetic parameters, genetic variants and anthropometric characteristics, concomitant medications, comorbidities, and coagulation parameters were assessed using appropriate statistical analyses. Results: Carriers of the ABCB1 rs2032582 G allele exhibited lower rivaroxaban exposure, as reflected by reduced AUC0–12h values compared with non-carriers (1817.43 ± 703.70 vs. 2442.96 ± 691.13 ng·h/mL, nominal p = 0.0369). Concomitant use of eplerenone was associated with increased rivaroxaban exposure. Body mass composition and impaired renal function were associated with rivaroxaban concentrations. In addition, associations between CYP3A4 rs2242480 genotype and several body size descriptors, including body weight or lean body mass, and selected coagulation parameters were observed in exploratory analyses. However, most nominal associations did not remain statistically significant after correction for multiple comparisons. After Benjamini–Hochberg correction, only impaired renal function, drug interactions and biological sex remained statistically significant factors, impacting rivaroxaban’s pharmacokinetics and anticoagulant parameters. Conclusions: Several genetic and clinical factors showed nominal association with rivaroxaban pharmacokinetics and coagulation parameters in this study. These findings should be interpreted as exploratory given the limited sample size and the number of statistical comparisons. Further studies in larger cohorts are needed to clarify the clinical relevance of genetic and clinical determinants of rivaroxaban exposure.
- Open Access
- 23 August 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 21 (6) , 2258-2266
Updated Focused Review of Hematological, Inflammatory, and Lipid Biomarkers in Acute Coronary Syndrome
At present hematological indices and biomarkers of inflammation that may be associated with atherosclerosis and the prediction of acute coronary syndromes (ACS) attract a lot of academic attention. This update focused review aims to provide an overview of selected ACS biomarkers: white blood cells, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, Systemic Inflammatory Index (SII), Systemic Inflammatory Response Index (SIRI) and Lipoprotein (a). Novel inflammatory-lipid biomarkers such as hsCRP to high density lipoprotein cholesterol (HDL-C) ratio, Neutrophils to HDL-C ratio, and Monocyte to HDL-C ratio may improve ACS diagnosis, risk stratification, clinical prognosis and optimal management. These indices are inexpensive and easily obtained in daily clinical practice. Artificial intelligence and genetic analysis may improve their diagnostic performance and guide clinical management. The recent data also emphasize that these indices may be a promising clinical tool for assessing ACS patients and monitoring the effectiveness of emerging anti-inflammatory strategies.
- 23 August 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 21 (6) , 2258-2266
Open AccessUpdated Focused Review of Hematological, Inflammatory, and Lipid Biomarkers in Acute Coronary Syndrome
At present hematological indices and biomarkers of inflammation that may be associated with atherosclerosis and the prediction of acute coronary syndromes (ACS) attract a lot of academic attention. This update focused review aims to provide an overview of selected ACS biomarkers: white blood cells, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, Systemic Inflammatory Index (SII), Systemic Inflammatory Response Index (SIRI) and Lipoprotein (a). Novel inflammatory-lipid biomarkers such as hsCRP to high density lipoprotein cholesterol (HDL-C) ratio, Neutrophils to HDL-C ratio, and Monocyte to HDL-C ratio may improve ACS diagnosis, risk stratification, clinical prognosis and optimal management. These indices are inexpensive and easily obtained in daily clinical practice. Artificial intelligence and genetic analysis may improve their diagnostic performance and guide clinical management. The recent data also emphasize that these indices may be a promising clinical tool for assessing ACS patients and monitoring the effectiveness of emerging anti-inflammatory strategies.
- Open Access
- 15 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (4) , 1096
Predictors of Revascularization in Patients with Unstable Angina
Background: The factors that determine the necessity of coronary artery revascularization in patients with unstable angina (UA) have been supported by limited data. Therefore, this study aimed to identify the predictors of revascularization in patients with UA. Methods: The study included the recorded data of 3668 patients with UA who underwent cardiac catheterization (age 66 ± 9.2, men 70%); 2615 of them (71%) underwent revascularization (percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG), or hybrid revascularization. The remaining 1053 patients (29%) had no significant coronary stenosis and were regarded as controls. Multivariable logistic regression analysis was performed to separate the predictors of revascularization. Results: It was found that severe angina (OR 2.7, 95%CI 1.9–3.7), male gender (OR 1.4, 95%CI 1.1–1.7), and hyperlipidemia were the predictors of revascularization. It was also noted that intraventricular conduction disorders including left and right bundle branch blocks and a history of previous revascularization and myocardial infarction were associated with lower odds of revascularization. Conclusion: Overall, however, the predictive value of the studied factors proved to be poor and may still point to the multifactorial nature of significant coronary artery stenosis and the need for revascularization in patients with UA.
- 15 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (4) , 1096
Open AccessPredictors of Revascularization in Patients with Unstable Angina
Background: The factors that determine the necessity of coronary artery revascularization in patients with unstable angina (UA) have been supported by limited data. Therefore, this study aimed to identify the predictors of revascularization in patients with UA. Methods: The study included the recorded data of 3668 patients with UA who underwent cardiac catheterization (age 66 ± 9.2, men 70%); 2615 of them (71%) underwent revascularization (percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft (CABG), or hybrid revascularization. The remaining 1053 patients (29%) had no significant coronary stenosis and were regarded as controls. Multivariable logistic regression analysis was performed to separate the predictors of revascularization. Results: It was found that severe angina (OR 2.7, 95%CI 1.9–3.7), male gender (OR 1.4, 95%CI 1.1–1.7), and hyperlipidemia were the predictors of revascularization. It was also noted that intraventricular conduction disorders including left and right bundle branch blocks and a history of previous revascularization and myocardial infarction were associated with lower odds of revascularization. Conclusion: Overall, however, the predictive value of the studied factors proved to be poor and may still point to the multifactorial nature of significant coronary artery stenosis and the need for revascularization in patients with UA.